|
Market Cap (5-Jul) $17,064,960 (1,393rd) |
Close (30-Jun) $0.012 |
Volume (30-Jun) 5,851,219 |
Shortsold (10-Feb) 98,846 (0.00%) (597th) |
|
52w High $6.00 |
52w Low $0.80 |
P/E - |
EPS -1.79 |
OSL released this announcement to the ASX on 22 October 2020, 8:35. The announcement is marked as price sensitive, and is 2 page(s) in length and 302.82kb in size.
You can view all announcements from OSL and see how they appear on a price chart on the announcements page.
At the date of this announcement, OSL was 0.010% short sold according to ASIC data. It was ranked the 619th most shorted stock on the ASX. It is now ranked as the 597th most shorted stock on the ASX with 0.002% of total shares short sold as of the latest reported data (10 February 2025).
| Other Recent Announcements from OSL | |
|---|---|
| Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer | 30 June 2023, 9:49 |
| Notification of cessation of securities - OSL | 29 June 2023, 17:51 |
| Ethics Committee Approves PANCOSIL Clinical Trial | 5 June 2023, 9:31 |
| OncoSil achieves first commercial sale | 22 October 2020, 8:35 |
| Appendix 4C - quarterly | 21 October 2020, 15:44 |
| Results of the OncoSil 2020 Annual General Meeting | 20 October 2020, 17:44 |
| Positive PanCO trial update on resected cohort | 20 October 2020, 8:41 |
You must be logged in to post a reply.
OncoSil Medical 